Showing posts with label GOG186H. Show all posts
Showing posts with label GOG186H. Show all posts
Monday, September 13, 2010
media: Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward
Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN® in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
Subscribe to:
Posts
(
Atom
)
